



## WPD Pharmaceuticals Announces Further Update to its Annual Filing and Extension For Q1 Filing

Vancouver, British Columbia / June 1, 2020 – WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), announces that, further to its news release dated April 28, 2020, the Company is expecting to file its audited financial statements for the year ended December 31, 2019 (the “Annual Filings”) by the extension date of June 15, 2020 pursuant to BC Instrument 51-515 *Temporary Exemption from Certain Corporate Finance Requirements* (“BCI 51-515”) and continues to work diligently with its auditors to file the Annual Filings by June 15, 2020.

### Update on Q1 Filing

The Company will also be relying on the temporary exemption pursuant to BCI 51-515 in respect to the following provisions:

- the requirement to file interim financial statements for the three months ended March 31, 2020 (the “**Financial Statements**”) within 60 days after the end of the Company’s interim period as required by section 4.4(b) of National Instrument 51-102 *Continuous Disclosure* (“**NI 51-102**”);
- the requirement to file management discussion and analysis (the “**MD&A**”) for the period covered by the Financial Statements within 60 days after the end of the Company’s interim period as required by section 5.1(2) of NI 51-102; and
- the requirement to file certifications of the Financial Statements (the “**Certificates**” and together with the Financial Statements, the “**Interim Filings**”) pursuant to section 5.1 of National Instrument 52-109 *Certification of Disclosure in Issuer’s Annual and Interim Filings* and section 4.4(b) [being the filing deadline for interim financial statements] of NI 51-102.

The Company is continuing to work diligently to file the Interim Filings by July 16, 2020.

The Company confirms that there have been no material developments, other than those disclosed through news releases.

Additionally, the Company advises that management and other insiders of the Company are subject to a trading black-out policy as described, in principle, in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

### About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with two US based public companies, respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from the two public companies includes 31 countries in Europe and Asia, including Russia.

### **On Behalf of the Board**

*'Mariusz Olejniczak'*

Mariusz Olejniczak  
CEO, WPD Pharmaceuticals

### **Contact**

Investor Relations  
Email: [investors@wpdpharmaceuticals.com](mailto:investors@wpdpharmaceuticals.com)  
Tel: 604-428-7050  
Web: [www.wpdpharmaceuticals.com](http://www.wpdpharmaceuticals.com)

*Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.*